Literature DB >> 20926560

Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection.

Natalie J Thornburg1, Bryan Shepherd, James E Crowe.   

Abstract

Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality. Previous studies have suggested that T-cell responses may contribute to RSV immunopathology, which could be driven by dendritic cells (DCs). DCs are productively infected by RSV, and during RSV infections, there is an increase of DCs in the lungs with a decrease in the blood. Pediatric populations are particularly susceptible to severe RSV infections; however, DC responses to RSV from pediatric populations have not been examined. In this study, primary isolated DCs from cord blood and adult peripheral blood were compared after RSV infection. Transcriptional profiling and biological network analysis identified transforming growth factor beta (TGF-β) and associated signaling molecules as differentially regulated in the two age groups. TGF-β1 was decreased in RSV-infected adult-blood DCs but increased in RSV-infected cord blood DCs. Coculture of adult RSV-infected DCs with autologous T cells induced secretion of gamma interferon (IFN-γ), interleukin 12p70 (IL-12p70), IL-2, and tumor necrosis factor alpha (TNF-α). Conversely, coculture of cord RSV-infected DCs and autologous T cells induced secretion of IL-4, IL-6, IL-1β, and IL-17. Addition of purified TGF-β1 to adult DC-T-cell cocultures reduced secretion of IFN-γ, IL-12p70, IL-2, and TNF-α, while addition of a TGF-β chemical inhibitor to cord DC-T-cell cocultures increased secretion of IL-12p70. These data suggest that TGF-β acts as a major regulator of RSV DC-T-cell responses, which could contribute to immunopathology during infancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926560      PMCID: PMC3004333          DOI: 10.1128/JVI.01273-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.

Authors:  L Gorelik; P E Fields; R A Flavell
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression.

Authors:  Jamila Chakir; Joanne Shannon; Sophie Molet; Motonori Fukakusa; Jack Elias; Michel Laviolette; Louis-Philippe Boulet; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

3.  A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children.

Authors:  Eun Hwa Choi; Hoan Jong Lee; Taiwoo Yoo; Stephen J Chanock
Journal:  J Infect Dis       Date:  2002-10-11       Impact factor: 5.226

4.  Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.

Authors:  E A Kurt-Jones; L Popova; L Kwinn; L M Haynes; L P Jones; R A Tripp; E E Walsh; M W Freeman; D T Golenbock; L J Anderson; R W Finberg
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

5.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.

Authors:  Daniel J Cua; Jonathan Sherlock; Yi Chen; Craig A Murphy; Barbara Joyce; Brian Seymour; Linda Lucian; Wayne To; Sylvia Kwan; Tatyana Churakova; Sandra Zurawski; Maria Wiekowski; Sergio A Lira; Daniel Gorman; Robert A Kastelein; Jonathon D Sedgwick
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

6.  Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates.

Authors:  Subramaniam Krishnan; Mary Craven; Robert C Welliver; Nafees Ahmad; Marilyn Halonen
Journal:  J Infect Dis       Date:  2003-07-10       Impact factor: 5.226

7.  Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms.

Authors:  Barbara Hoebee; Edwin Rietveld; Louis Bont; Marijke van Oosten; Hennie M Hodemaekers; Nico J D Nagelkerke; Herman J Neijens; Jan L L Kimpen; Tjeerd G Kimman
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

8.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

9.  Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation.

Authors:  Leonid Gorelik; Stephanie Constant; Richard A Flavell
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

10.  The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease.

Authors:  M F Neurath; B Weigmann; S Finotto; J Glickman; E Nieuwenhuis; H Iijima; A Mizoguchi; E Mizoguchi; J Mudter; P R Galle; A Bhan; F Autschbach; B M Sullivan; S J Szabo; L H Glimcher; R S Blumberg
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

View more
  24 in total

1.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

Review 2.  Unique aspects of the perinatal immune system.

Authors:  Xiaoming Zhang; Dania Zhivaki; Richard Lo-Man
Journal:  Nat Rev Immunol       Date:  2017-06-19       Impact factor: 53.106

3.  TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages.

Authors:  Jocelyn R Grunwell; Samantha M Yeligar; Susan Stephenson; Xiao Du Ping; Theresa W Gauthier; Anne M Fitzpatrick; Lou Ann S Brown
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

4.  Lack of Activation Marker Induction and Chemokine Receptor Switch in Human Neonatal Myeloid Dendritic Cells in Response to Human Respiratory Syncytial Virus.

Authors:  Cyril Le Nouën; Philippa Hillyer; Eric Levenson; Craig Martens; Ronald L Rabin; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  Alveolar macrophages contribute to the pathogenesis of human metapneumovirus infection while protecting against respiratory syncytial virus infection.

Authors:  Deepthi Kolli; Meera R Gupta; Elena Sbrana; Thangam S Velayutham; Hong Chao; Antonella Casola; Roberto P Garofalo
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

6.  Krüppel-like factor 6 regulates transforming growth factor-β gene expression during human respiratory syncytial virus infection.

Authors:  Victoria Mgbemena; Jesus Segovia; TeHung Chang; Santanu Bose
Journal:  Virol J       Date:  2011-08-17       Impact factor: 4.099

7.  Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis.

Authors:  Steven B Smith; William Dampier; Aydin Tozeren; James R Brown; Michal Magid-Slav
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

8.  Perinatal lamb model of respiratory syncytial virus (RSV) infection.

Authors:  Rachel J Derscheid; Mark R Ackermann
Journal:  Viruses       Date:  2012-10-23       Impact factor: 5.048

9.  Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB.

Authors:  Natalie J Thornburg; Sarah L Hayward; James E Crowe
Journal:  mBio       Date:  2012-12-18       Impact factor: 7.867

Review 10.  Th17 lymphocytes in respiratory syncytial virus infection.

Authors:  Jonas Bystrom; Nasra Al-Adhoubi; Mohammed Al-Bogami; Ali S Jawad; Rizgar A Mageed
Journal:  Viruses       Date:  2013-03-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.